Brief: Cns Pharmaceuticals Announces Dosing Of First Patient In Europe/France In Ongoing Trial Evaluating Berubicin For Treatment Of GBM

CNS Pharmaceuticals

02/11/2022 15:36

Nov 2 (Reuters) - CNS Pharmaceuticals Inc  CNSP.O :
    * CNS PHARMACEUTICALS ANNOUNCES DOSING OF FIRST PATIENT IN
EUROPE/FRANCE IN ONGOING POTENTIALLY PIVOTAL GLOBAL TRIAL
EVALUATING BERUBICIN FOR THE TREATMENT OF GBM
    * FDA HAS GRANTED CNS PHARMACEUTICALS FAST TRACK DESIGNATION
FOR
BERUBICIN
    * CO HAS ALSO RECEIVED ORPHAN DRUG DESIGNATION FROM FDA

Source text for Eikon:  ID:nPn9fyFWra 
Further company coverage:  CNSP.O 
 ((Reuters.Briefs@thomsonreuters.com;;))